Evidence map›Paper›PMID 38893195›Full record

ArticleCancers2024

Influence of Previous Therapy for Neutropenia Caused by Combination Therapy of Ramucirumab and Docetaxel.

Hiroyuki Ohno, Takahiro Hayashi, Shota Torii, Miduki Niwa, Nanae Katagiri, Yuri Nakao, Shota Mano, Norio Takimoto, Tomoyuki Hirashita

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hiroyuki OhnoDepartment of Pharmacy, Gifu Prefectural General Medical Center, Gifu 500-8717, Japan.
Takahiro HayashiCollege of Pharmacy, Kinjo Gakuin University, Nagoya 463-8521, Japan.ORCID 0000-0002-9686-6903
Shota ToriiDepartment of Pharmacy, Kariya Toyota General Hospital, Kariya 448-8505, Japan.
Miduki NiwaCollege of Pharmacy, Kinjo Gakuin University, Nagoya 463-8521, Japan.
Nanae KatagiriCollege of Pharmacy, Kinjo Gakuin University, Nagoya 463-8521, Japan.
Yuri NakaoCollege of Pharmacy, Kinjo Gakuin University, Nagoya 463-8521, Japan.
Shota ManoDepartment of Pharmacy, Gifu Prefectural General Medical Center, Gifu 500-8717, Japan.
Norio TakimotoDepartment of Pharmacy, Kariya Toyota General Hospital, Kariya 448-8505, Japan.
Tomoyuki HirashitaDepartment of Pharmacy, Gifu Prefectural General Medical Center, Gifu 500-8717, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, the influence of previous immune checkpoint inhibitor (ICI) therapy with ramucirumab (RAM) + docetaxel (DTX) therapy on the occurrence of severe neutropenia in patients with non-small cell lung cancer (NSCLC) was evaluated, taking into account the influences of cytotoxic chemotherapy used in pretreatment. The study participants included patients who received a combination therapy of RAM and DTX as cancer chemotherapy for NSCLC. The influences of previous ICI treatment and pretreatment with cytotoxic anticancer agents on the development of grade ≥ 3 neutropenia were analysed. A total of 89 patients, including 50 with and 39 without a history of ICI treatment, were analysed. Kaplan-Meier curves showed a significant difference in the influence of previous ICI treatment on the development of grade ≥ 3 neutropenia (

Indexed as

combination therapy of ramucirumab and docetaxelcytotoxic chemotherapyimmune checkpoint inhibitorneutropenia

Identifiers

PMID38893195
PMCPMC11171386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.